Association Between Preonset Anti-hypertensive Treatment and Intracerebral Hemorrhage Mortality: A Cohort Study From CHEERY

Hypertension is the most prevalent risk factor for intracerebral hemorrhage (ICH). In this study, we investigated whether preonset anti-hypertensive therapy could affect the outcomes of ICH. This was a retrospective cohort study. A total of 3,460 consecutive patients with acute first-ever ICH from 31 recruitment sites were enrolled into the Chinese cerebral hemorrhage: mechanism and intervention (CHERRY) study from December 1, 2018 to November 30, 2020, and 2,140 (61.8%) with hypertension history were entered into the analysis. Only 586 patients (27.4%) with hypertension history currently received anti-hypertensive therapy, and which was associated with lower systolic blood pressure (SBP) and diastolic blood pressure (DBP) on admission (SBP, = 0.008; DBP, = 0.017), less hematoma volume (9.8 vs. 11%, = 0.006), and lower all-cause mortality at 3 months (15.3 vs. 19.8%, OR = 0.728, = 0.016). In multivariable analysis, adjusting for age, gender, residence, ischemic stroke history, admission SBP and DBP, and current use of antihypertension were significantly associated with lower adjusted hazard ratios (HRs) for all-cause mortality at discharge (adjusted HR, 0.497, = 0.012), 30 days (adjusted HR, 0.712, = 0.015), and 90 days (adjusted HR, 0.766, = 0.030). However, after adjusting the variable of hematoma volume, the mortality between the two groups was not significantly different. Preonset anti-hypertensive therapy was associated with lower mortality of ICH, which somewhat depended on hematoma volume.